CBIO — Crescent Biopharma Share Price
0.000.00%
Last trade - 00:00- $517.25m
- $332.09m
- $10.84m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.88 | ||
| Price to Tang. Book | 2.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 43.53 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -88.21% | ||
| Return on Equity | -179.1% | ||
| Operating Margin | -1372.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.16 | 0.07 | 0.01 | n/a | 10.84 | 1.83 | 5.58 | 1.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Directors
- Timothy Pearson NEC (53)
- Harout Semerjian CEO (50)
- John Magnani CFD (68)
- Brian Hahn CFO (46)
- Eric Feldman SVP (65)
- Armand Girard SVP (52)
- Rachel King DRC (61)
- Patricia Andrews IND (63)
- Mark Goldberg IND (67)
- Scott Jackson IND (56)
- Daniel Junius IND (68)
- Scott Koenig IND (69)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- June 13th, 2025
- Public Since
- January 10th, 2014
- No. of Shareholders
- 66
- No. of Employees
- 44
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 27,571,935
- Address
- 300 Fifth Avenue, WALTHAM, 02451
- Web
- https://www.crescentbiopharma.com/
- Phone
- +1 6174305595
- Auditors
- Ernst & Young LLP
Upcoming Events for CBIO
Crescent Biopharma Inc at Stifel Virtual Targeted Oncology Forum
Crescent Biopharma Inc at TD Cowen Oncology Innovation Summit (Virtual)
Crescent Biopharma Inc Annual Shareholders Meeting
Similar to CBIO
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
FAQ
What is the Crescent Biopharma share price?
As of Today at 11:06 UTC, shares in Crescent Biopharma are trading at $18.76. This share price information is delayed by 15 minutes.
How has the Crescent Biopharma share price performed this year?
Shares in Crescent Biopharma last closed at $18.76 and the price had moved by -22.64% over the past 365 days. In terms of relative price strength the Crescent Biopharma share price has underperformed the S&P500 Index by -40.82% over the past year.
What are the analyst and broker recommendations for Crescent Biopharma?
The overall consensus recommendation for Crescent Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Crescent Biopharma dividend yield?
Crescent Biopharma does not currently pay a dividend.
Does Crescent Biopharma pay a dividend?
Crescent Biopharma does not currently pay a dividend.
When does Crescent Biopharma next pay dividends?
Crescent Biopharma does not currently pay a dividend.
How do I buy Crescent Biopharma shares?
To buy shares in Crescent Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Crescent Biopharma?
As of the previous close price of $18.76, shares in Crescent Biopharma had a market capitalisation of $517.25m.
Where are Crescent Biopharma shares listed?
Here are the trading details for Crescent Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CBIO
What kind of share is Crescent Biopharma?
Based on an overall assessment of its quality, value and momentum Crescent Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Crescent Biopharma share price forecast for 2026?
The analyst consensus target price for shares in Crescent Biopharma is $29.50. That is 57.25% above the last closing price of $18.76.
Analysts covering Crescent Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$3.37 for the next financial year.
Find out moreWhat is the trend in the Crescent Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Crescent Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +31.94%.
As of the last closing price of $18.76, shares in Crescent Biopharma were trading +39.07% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Crescent Biopharma PE Ratio?
The Crescent Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Crescent Biopharma?
Crescent Biopharma's management team is headed by:
- Timothy Pearson - NEC
- Harout Semerjian - CEO
- John Magnani - CFD
- Brian Hahn - CFO
- Eric Feldman - SVP
- Armand Girard - SVP
- Rachel King - DRC
- Patricia Andrews - IND
- Mark Goldberg - IND
- Scott Jackson - IND
- Daniel Junius - IND
- Scott Koenig - IND